Lb Pharmaceuticals (LBRX) Free Cash Flow (2024 - 2026)

Lb Pharmaceuticals' Free Cash Flow history runs 3 years deep, the most recent figure standing at -$23.3 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 186.32% year-over-year to -$23.3 million in Q1 2026; TTM through Mar 2026 was -$49.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$35.3 million, up 34.5% from the prior year.
• Free Cash Flow declined to -$23.3 million in Q1 2026 per LBRX's latest filing, from -$18.1 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$5.9 million in Q4 2024 and bottomed at -$23.3 million in Q1 2026.
• The 3-year median for Free Cash Flow is -$13.1 million (2025), against an average of -$13.9 million.
• Across the five-year window, Free Cash Flow plunged 207.3% in 2025 and slumped 186.32% in 2026, its largest moves.
• Year by year, Free Cash Flow stood at -$5.9 million in 2024, then plunged by 207.3% to -$18.1 million in 2025, then retreated by 28.62% to -$23.3 million in 2026.
• Per Business Quant, the three latest LBRX Free Cash Flow figures stand at -$23.3 million (Q1 2026), -$18.1 million (Q4 2025), and -$8.1 million (Q1 2025).